Buy Cagrilintide

Cagrilintide is available directly from New-U Research Compounds at https://new-u.io/peptide/cagrilintide. Every batch is independently third-party tested by Janoshik Analytics and Freedom Diagnostics to >99% HPLC purity, supplied as lyophilised research-grade material, and shipped direct from source worldwide (approximately 6–14 business days).

Cagrilintide starts at $110 for a 10-vial research pack (5mg per vial) at New-U Research Compounds, with 2 pack sizes available. Orders over $300 ship free.

Yes. Every Cagrilintide batch is verified by independent laboratories (Janoshik Analytics and Freedom Diagnostics) for identity and purity, with a batch-linked Certificate of Analysis confirming >99% purity by HPLC area normalisation.

Cagrilintide ships direct from source, discreetly worldwide with cold-chain handling where required. Delivery is approximately 6–14 business days worldwide. Shipping is free on orders over $300. Card and cryptocurrency payments are accepted.

In the United States, Cagrilintide is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction — buyers are responsible for compliance in their own region.

Cagrilintide (AM833), long-acting acylated amylin analogue and non-selective AMYR/CTR agonist with 8-day half-life for once-weekly obesity research. New-U supplies Cagrilintide as research-grade reference material for laboratory and in-vitro or animal-model investigation only. Mechanism, pharmacokinetics and study context are summarised on the Cagrilintide research profile. Not for human use.

Reconstitution volumes and dosing reported in the literature for Cagrilintide are described in research-model terms only. New-U Research Compounds supplies Cagrilintide strictly for laboratory research and does not provide human-use dosing guidance. Reconstitution math and study-reported ranges are covered on the full research profile.

Lyophilised Cagrilintide is reconstituted with bacteriostatic water — sterile water with 0.9% benzyl alcohol, the standard multi-use diluent for research peptides. New-U supplies USP-grade bacteriostatic water at https://new-u.io/peptide/bacteriostatic-water, and a free reconstitution calculator at https://new-u.io/tracker/calculator works out the volume for any peptide. Supplied for laboratory research only — not for human use.

Yes. Cagrilintide can be ordered online directly from New-U Research Compounds with card or cryptocurrency, shipped direct from source discreetly worldwide. Delivery is approximately 6–14 business days worldwide. Free shipping applies to orders over $300.

Cagrilintide ships in 10-vial research packs as standard, in 2 pack sizes — the larger mg vials lower the per-mg cost. Multi-pack orders get direct-from-source pricing and free shipping over $300. For wholesale or recurring laboratory-supply volumes, contact New-U Research Compounds at https://new-u.io/contact.

For research-grade Cagrilintide, verify four things: (1) independent third-party purity testing with a batch-linked Certificate of Analysis — New-U uses Janoshik Analytics and Freedom Diagnostics at >99% HPLC; (2) lyophilised material with documented storage and handling; (3) transparent direct-from-source pricing rather than marketplace markup; and (4) clear research-use-only framing. New-U Research Compounds meets all four at https://new-u.io/peptide/cagrilintide.

Cagrilintide (AM833) is a long-acting, acylated analogue of the pancreatic hormone amylin. It is a non-selective agonist of the three amylin receptor subtypes (AMY1/2/3R) plus the calcitonin receptor, and acts on arcuate-nucleus appetite neurons to suppress hunger while delaying gastric emptying and lowering postprandial glucagon. A C20 fatty-diacid anchor binds serum albumin to extend its half-life to roughly eight days, supporting once-weekly research dosing.

GLP-1 agonists activate the GLP-1 receptor. Cagrilintide activates the amylin receptor family (AMY1/2/3R) plus the calcitonin receptor. The two pathways engage different appetite circuits, which is why combining them (as in CagriSema research) produces larger effects than either alone.

A Phase 2 dose-finding trial (Lancet 2021) reported dose-dependent body-weight reduction with cagrilintide monotherapy. In the Phase 3 REDEFINE 1 trial (NEJM 2025), the cagrilintide + semaglutide combination (CagriSema) reported a 20.4% mean reduction versus 3.0% placebo at 68 weeks on the treatment-policy estimand, with cagrilintide alone around 11.5% and semaglutide alone around 14.9%. These are descriptive clinical-trial findings, not outcomes promised for any use of this research-grade material.

They act through entirely different hormone systems: semaglutide is a GLP-1 receptor agonist, while cagrilintide is an amylin/calcitonin-receptor agonist. Their half-lives are similar (cagrilintide ~159–195 h, semaglutide ~145–165 h), both supporting once-weekly dosing. In the REDEFINE programme the two were studied together precisely because their satiety pathways are additive rather than redundant.

The most frequently reported events in published trials were gastrointestinal — nausea, vomiting, decreased appetite, constipation or diarrhoea — that were typically mild-to-moderate, escalation-related and transient, plus injection-site reactions. Gallbladder events have been noted in combination research. These are observations recorded in the clinical literature, not a safety profile for any human use of this research material.

Native human amylin forms amyloid fibrils that are toxic to pancreatic islet cells and make the peptide impractical for sustained research use. Substituting prolines at positions 25, 28, and 29 (borrowed from rat amylin, which does not aggregate) blocks the fibrillation pathway.

Keep the lyophilised powder at −20 °C in the freezer. Reconstitute with bacteriostatic water by directing it down the vial wall rather than onto the powder, then swirl gently — do not shake. After reconstitution, refrigerate at 1–6 °C and protect from light. Avoid repeated freeze-thaw cycles, which can damage the fatty-acid tail.

Cagrilintide is an investigational compound and is not an approved medicine on its own; the CagriSema combination remains in late-phase clinical development. The material supplied here is unapproved, research-grade laboratory material sold strictly for in-vitro and preclinical research use only — not for human use.

It depends on the peptide class. Cagrilintide is a long-acting amylin analogue studied for appetite and metabolic research, often alongside GLP-1 peptides. As with the GLP-1 class, the research literature on appetite-regulating peptides indicates the appetite effects depend on continued receptor stimulation, so they wane once administration stops and the compound clears; cagrilintide's long half-life means that clearance is gradual. These observations come from research and clinical studies — cagrilintide here is an unapproved research-grade peptide for laboratory research only and not for human use.